Marketing Authorization Application for Lipsovir® submitted to European regulatory authorities.

Marketing Authorization Application for Lipsovir® submitted to European
regulatory authorities.

Medivir has now submitted an application for marketing authorization to the
European regulatory authorities for Lipsovir®, a topical product for prevention
and treatment of cold sores. 

Lipsovir® is a patented combination of hydrocortisone (an anti-inflammatory
agent) and acyclovir (an antiviral agent) in a proprietary cream base developed
by Medivir.

The clinical phase III program demonstrated that the development of cold sores
can be prevented with early treatment initiation, an effect that currently
available products for this indication lack. Lipsovir® thereby provides
individuals prone to recurrent cold sores with a clinically important benefit
compared to currently available products. 

“We have achieved a substantial and important milestone for Lipsovir® in filing
registration applications in both USA and Europe”, says Börje Darpö, Head of
Medivir's clinical development department.


For additional information please contact
Rein Piir, CFO & VP, Investor Relations at Medivir, +46 8 5468 3123 or +46 708
537292

For more information on Medivir, please see the company website www.medivir.se